Praxis Precision Medicines (PRAX) Competitors $45.85 +1.34 (+3.01%) Closing price 04:00 PM EasternExtended Trading$45.74 -0.11 (-0.23%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. PTGX, CPRX, CRNX, MTSR, VKTX, MOR, SRRK, KYMR, MLTX, and IMVTShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Protagonist Therapeutics Catalyst Pharmaceuticals Crinetics Pharmaceuticals Metsera Viking Therapeutics MorphoSys Scholar Rock Kymera Therapeutics MoonLake Immunotherapeutics Immunovant Praxis Precision Medicines (NASDAQ:PRAX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking. Do analysts recommend PRAX or PTGX? Praxis Precision Medicines currently has a consensus target price of $109.90, suggesting a potential upside of 139.69%. Protagonist Therapeutics has a consensus target price of $65.44, suggesting a potential upside of 16.10%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PRAX or PTGX? Protagonist Therapeutics received 239 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 75.00% of users gave Praxis Precision Medicines an outperform vote while only 61.55% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformPraxis Precision MedicinesOutperform Votes5475.00% Underperform Votes1825.00% Protagonist TherapeuticsOutperform Votes29361.55% Underperform Votes18338.45% Do institutionals & insiders have more ownership in PRAX or PTGX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is PRAX or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Praxis Precision Medicines' net margin of -9,409.22%. Protagonist Therapeutics' return on equity of 34.68% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-9,409.22% -54.86% -50.52% Protagonist Therapeutics 52.76%34.68%30.98% Which has more volatility and risk, PRAX or PTGX? Praxis Precision Medicines has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Does the media refer more to PRAX or PTGX? In the previous week, Protagonist Therapeutics had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 6 mentions for Praxis Precision Medicines. Protagonist Therapeutics' average media sentiment score of 0.78 beat Praxis Precision Medicines' score of 0.32 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, PRAX or PTGX? Protagonist Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.12M114.99-$123.28M-$10.72-4.28Protagonist Therapeutics$207.80M16.81-$78.96M$0.7575.16 SummaryProtagonist Therapeutics beats Praxis Precision Medicines on 14 of the 19 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$933.92M$6.83B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-4.458.7927.2020.17Price / Sales114.99263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book5.796.677.114.72Net Income-$123.28M$143.49M$3.23B$247.80M7 Day Performance11.29%6.34%4.61%3.36%1 Month Performance19.56%15.43%13.35%9.71%1 Year Performance13.04%6.87%31.75%14.41% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.7638 of 5 stars$45.85+3.0%$109.90+139.7%+9.8%$933.92M$8.12M-4.45110Positive NewsPTGXProtagonist Therapeutics2.2858 of 5 stars$50.15+5.6%$65.44+30.5%+60.0%$3.11B$207.80M18.85120Analyst UpgradeCPRXCatalyst Pharmaceuticals4.6496 of 5 stars$24.90-0.2%$32.29+29.7%+65.4%$3.04B$534.65M21.1080CRNXCrinetics Pharmaceuticals3.6137 of 5 stars$31.88+4.5%$74.56+133.9%-27.8%$2.98B$760,000.00-8.55210Positive NewsAnalyst RevisionMTSRMetseraN/A$28.12+5.2%$47.00+67.1%N/A$2.95BN/A0.0081Trending NewsAnalyst ForecastGap UpVKTXViking Therapeutics4.5586 of 5 stars$26.12-2.5%$87.15+233.7%-50.8%$2.93BN/A-26.1220Options VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.1221 of 5 stars$29.76+2.6%$42.67+43.4%+258.3%$2.83B$33.19M-12.66140KYMRKymera Therapeutics2.0229 of 5 stars$43.13+45.5%$55.69+29.1%+43.1%$2.81B$58.89M-18.43170High Trading VolumeMLTXMoonLake Immunotherapeutics2.1072 of 5 stars$41.16+5.5%$78.71+91.2%+11.9%$2.63BN/A-31.912Analyst RevisionIMVTImmunovant1.4327 of 5 stars$15.41+3.8%$38.33+148.8%-35.3%$2.62BN/A-5.88120Positive NewsAnalyst Revision Related Companies and Tools Related Companies Protagonist Therapeutics Competitors Catalyst Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Metsera Competitors Viking Therapeutics Competitors MorphoSys Competitors Scholar Rock Competitors Kymera Therapeutics Competitors MoonLake Immunotherapeutics Competitors Immunovant Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRAX Stock Free PRAX Stock Alerts